iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical
Company profile
Ticker
IOVA
Exchange
Website
CEO
Maria Fardis
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
FREIGHT MANAGEMENT CORP, Genesis Biopharma, Inc, Lion Biotechnologies, Inc.
SEC CIK
Corporate docs
Subsidiaries
Iovance Biotherapeutics GmbH, a company • Iovance Biotherapeutics B.V., a company • Iovance Biotherapeutics Manufacturing LLC, a limited liability company • Iovance Biotherapeutics UK Ltd, a limited company • Iovance Biotherapeutics UK SP Ltd, a limited company • Iovance Biotherapeutics Canada Inc., a company ...
IRS number
753254381
IOVA stock data
Latest filings (excl ownership)
8-K
Other Events
3 Apr 24
8-K
Departure of Directors or Certain Officers
29 Mar 24
8-K
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
4 Mar 24
8-K
Other Events
29 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023
28 Feb 24
8-K
Other Events
22 Feb 24
424B5
Prospectus supplement for primary offering
21 Feb 24
8-K
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
20 Feb 24
8-K
Iovance’s AMTAGVITM (lifileucel) Receives U.S. FDA Accelerated Approval
20 Feb 24
Transcripts
IOVA
Earnings call transcript
2023 Q4
28 Feb 24
IOVA
Earnings call transcript
2023 Q3
7 Nov 23
IOVA
Earnings call transcript
2023 Q2
8 Aug 23
IOVA
Earnings call transcript
2023 Q1
9 May 23
IOVA
Earnings call transcript
2022 Q4
28 Feb 23
IOVA
Earnings call transcript
2022 Q3
4 Nov 22
IOVA
Earnings call transcript
2022 Q2
5 Aug 22
IOVA
Earnings call transcript
2022 Q1
6 May 22
IOVA
Earnings call transcript
2021 Q4
25 Feb 22
IOVA
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
4
Frederick G Vogt
17 Apr 24
4
FINCKENSTEIN FRIEDRICH GRAF
17 Apr 24
4
IGOR BILINSKY
17 Apr 24
SC 13D/A
Quogue Capital LLC
19 Mar 24
4
FINCKENSTEIN FRIEDRICH GRAF
6 Mar 24
4
Frederick G Vogt
6 Mar 24
4
IGOR BILINSKY
6 Mar 24
4
WENDY L YARNO
5 Mar 24
4
Wayne P. Rothbaum
5 Mar 24
4
Frederick G Vogt
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 334.15 mm | 334.15 mm | 334.15 mm | 334.15 mm | 334.15 mm | 334.15 mm |
Cash burn (monthly) | (no burn) | (no burn) | 39.45 mm | 37.19 mm | 28.03 mm | 29.63 mm |
Cash used (since last report) | n/a | n/a | 269.74 mm | 254.30 mm | 191.62 mm | 202.56 mm |
Cash remaining | n/a | n/a | 64.41 mm | 79.85 mm | 142.53 mm | 131.59 mm |
Runway (months of cash) | n/a | n/a | 1.6 | 2.1 | 5.1 | 4.4 |
Institutional ownership, Q3 2023
84.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 226 |
Opened positions | 40 |
Closed positions | 32 |
Increased positions | 106 |
Reduced positions | 52 |
13F shares | Current |
---|---|
Total value | 947.24 bn |
Total shares | 236.89 mm |
Total puts | 2.08 mm |
Total calls | 5.92 mm |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Quogue Capital | 25.00 mm | $131.75 mm |
Vanguard | 22.14 mm | $100.75 bn |
MHR Fund Management | 20.00 mm | $90.99 bn |
BLK Blackrock | 18.38 mm | $83.61 bn |
STT State Street | 16.73 mm | $76.13 bn |
Perceptive Advisors | 11.96 mm | $54.43 bn |
Millennium Management | 7.82 mm | $35.58 bn |
Pictet Asset Management Holding | 6.91 mm | $31.46 bn |
Avoro Capital Advisors | 6.70 mm | $30.49 bn |
Artisan Partners Limited Partnership | 5.04 mm | $22.92 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Bilinsky Igor | Common Stock | Payment of exercise | Dispose F | No | No | 11.89 | 1,427 | 16.97 k | 38,026 |
15 Apr 24 | Bilinsky Igor | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,812 | 0.00 | 39,453 |
15 Apr 24 | Bilinsky Igor | RSU Common stock | Option exercise | Dispose M | No | No | 0 | 2,812 | 0.00 | 8,439 |
15 Apr 24 | Finckenstein Friedrich Graf | Common Stock | Payment of exercise | Dispose F | No | No | 11.89 | 1,427 | 16.97 k | 42,562 |
15 Apr 24 | Finckenstein Friedrich Graf | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,812 | 0.00 | 43,989 |
15 Apr 24 | Finckenstein Friedrich Graf | RSU Common stock | Option exercise | Dispose M | No | No | 0 | 2,812 | 0.00 | 8,439 |
15 Apr 24 | Frederick G Vogt | Common Stock | Payment of exercise | Dispose F | No | No | 11.89 | 8,851 | 105.24 k | 141,334 |
15 Apr 24 | Frederick G Vogt | Common Stock | Option exercise | Acquire M | No | No | 0 | 20,834 | 0.00 | 150,185 |
15 Apr 24 | Frederick G Vogt | RSU Common stock | Option exercise | Dispose M | No | No | 0 | 20,834 | 0.00 | 62,504 |
4 Mar 24 | Finckenstein Friedrich Graf | Common Stock | Payment of exercise | Dispose F | No | No | 16.96 | 8,053 | 136.58 k | 41,177 |
News
AHN Cancer Institute To Offer Groundbreaking Treatment For Metastatic Melanoma; The One-Time Treatment, Made By Iovance Biotherapeutics, Is The First FDA-Approved T-Cell Therapy For Solid Tumors
22 Apr 24
10 Health Care Stocks With Whale Alerts In Today's Session
19 Mar 24
Piper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Know
14 Mar 24
Piper Sandler Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19
14 Mar 24
Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics
13 Mar 24
Press releases
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
24 Apr 24
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
19 Apr 24
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
22 Mar 24
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
4 Mar 24
Iovance Biotherapeutics to Present at Upcoming Conferences
1 Mar 24